News Releases | Subscribe

October 8, 2019

Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting

SALT LAKE CITY, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that it will present results from five studies at the 2019 American Society of Human Genetics (ASHG) annual meeting being held Oct.

Read More

September 25, 2019

Myriad Genetics Expands Board of Directors with Two Additional Members

Colleen F. Reitan and Lee N. Newcomer, M.D., Elected to Myriad’s Board of Directors SALT LAKE CITY, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced the election of

Read More

September 16, 2019

Myriad Announces Research Collaboration with University of Leeds

Clinical Utility Study will Evaluate the Prolaris® Test in Men with Prostate Cancer SALT LAKE CITY, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced it will collaborate with the Leeds Centre for

Read More

August 13, 2019

Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2019 Financial Results

Total Fourth-Quarter Revenues of $215.4 Million Fourth-Quarter Diluted EPS of ($0.06) and Adjusted EPS of $0.41 SALT LAKE CITY, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today

Read More

August 6, 2019

Myriad to Announce Fiscal Fourth-Quarter 2019 Financial Results on August 13, 2019

SALT LAKE CITY, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal fourth-quarter 2019 sales and earnings conference call with investors and analysts at 4:30 p.m.

Read More

May 7, 2019

Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results

Total Third-Quarter Revenues of $216.6 Million, Up 18 Percent Third-Quarter Diluted EPS of $0.09 and Adjusted EPS of $0.46, Up 35 Percent SALT LAKE CITY, May 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in personalized medicine, today

Read More

September 25, 2019

Myriad Genetics Expands Board of Directors with Two Additional Members

Colleen F. Reitan and Lee N. Newcomer, M.D., Elected to Myriad’s Board of Directors SALT LAKE CITY, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced the election of

Read More

August 30, 2019

Myriad Genetics to Present at the 2019 Morgan Stanley Global Healthcare Conference

SALT LAKE CITY, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Morgan Stanley Global Healthcare Conference at 8:35 a.m.

Read More

August 6, 2019

Myriad to Announce Fiscal Fourth-Quarter 2019 Financial Results on August 13, 2019

SALT LAKE CITY, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal fourth-quarter 2019 sales and earnings conference call with investors and analysts at 4:30 p.m.

Read More

October 8, 2019

Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting

SALT LAKE CITY, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that it will present results from five studies at the 2019 American Society of Human Genetics (ASHG) annual meeting being held Oct.

Read More

September 16, 2019

Myriad Announces Research Collaboration with University of Leeds

Clinical Utility Study will Evaluate the Prolaris® Test in Men with Prostate Cancer SALT LAKE CITY, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced it will collaborate with the Leeds Centre for

Read More

September 5, 2019

Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment

65 Percent of Patients Remained on Active Surveillance for More than Four Years SALT LAKE CITY, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced publication of results

Read More

October 8, 2019

Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting

SALT LAKE CITY, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that it will present results from five studies at the 2019 American Society of Human Genetics (ASHG) annual meeting being held Oct.

Read More

September 16, 2019

Myriad Announces Research Collaboration with University of Leeds

Clinical Utility Study will Evaluate the Prolaris® Test in Men with Prostate Cancer SALT LAKE CITY, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced it will collaborate with the Leeds Centre for

Read More

September 5, 2019

Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment

65 Percent of Patients Remained on Active Surveillance for More than Four Years SALT LAKE CITY, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced publication of results

Read More

Myriad Corporate Presentation
Fact Sheet
Company Milestones